T-Therapeutics
PrivateLast Round
Series B
Nov 5, 2026
Total Funding Raised
$224M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
T-Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Series B round in November 2026.
T-Therapeutics is a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus® discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
T-Therapeutics Comparables
Compare T-Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adimab | 85% | |
| Engimmune Therapeutics | 83% | |
| EvolveImmune Therapeutics | 82% |
For institutional investors. Book with your work email.
T-Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 5, 2026 | ||||
| Series A Extension | Nov 13, 2025 | ||||
| Series A | Nov 15, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
T-Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Digitalis Ventures | Series A Extension, Series B, Series A |
| BGF | Series A Extension, Series B |
| F-Prime Capital | Series A |
| M Ventures | Series B |
| British Business Bank | Series B |
| Advent Life Sciences | Series B |
| Cambridge Enterprise | Series A, Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2026
Developing a program aimed at solid tumors.
- Nov 5, 2026
$133M round led by Advent Life Sciences and British Business Bank.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 6, 2026
T-Therapeutics is developing a programme aimed at solid tumours using TCR-CD3 bispecific therapy designed to help the immune system identify and attack specific disease-causing cells.
- receives_financingNov 5, 2026
T-Therapeutics receives $91M in Series A financing, expanded by $32M in Nov '25 from its original $59M financing in 2023.
- is_developingNov 5, 2026
T-Therapeutics is developing a different type of bispecific therapy designed to recognize proteins that conventional antibody-based drugs cannot easily reach, with two experimental T-cell engager therapies advancing toward clinical trials in the United Kingdom.
- hiresNov 5, 2026
T-Therapeutics appoints Dr. Kirsty Crame as Chief Development Officer to oversee the translational and clinical development of its pipeline.
- receives_financingNov 5, 2026
T-Therapeutics closes an oversubscribed $133M Series B financing co-led by Advent Life Sciences and British Business Bank, with participation from new and existing investors, to fund clinical development and proof-of-concept studies for TCR-CD3 bispecific programs in cancer and autoimmune disease in United Kingdom on Nov 5th '26.
For institutional investors. Book with your work email.
T-Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about T-Therapeutics's valuation, stock price, and market status.
Is T-Therapeutics a public or private company?
T-Therapeutics is a private company.
What is the current stock price of T-Therapeutics?
T-Therapeutics is a private company, so its shares have no public market price. Caplight tracks T-Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is T-Therapeutics worth (valuation)?
Valuation information for T-Therapeutics is not publicly available.
Can I buy T-Therapeutics stock?
T-Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was T-Therapeutics's last funding round?
T-Therapeutics's most recent funding round was Series B on November 5, 2026.
Who are the main investors in T-Therapeutics?
Key investors in T-Therapeutics include Digitalis Ventures, F-Prime Capital, British Business Bank, Advent Life Sciences, Cambridge Innovation Capital.
Will T-Therapeutics IPO soon?
No public IPO plans have been announced for T-Therapeutics.
How can I track T-Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in T-Therapeutics's shares on secondary markets.